UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                         Date of Report: April 27, 2005

                                 CYTOMEDIX, INC.
             (Exact name of registrant as it appears in its charter)

            Delaware                     0-28443                  23-3011702
(State or other jurisdiction    (Commission File Number)         (IRS Employer
      of incorporation)                                      Identification No.)

                         416 Hungerford Drive, Suite 330
                            Rockville, Maryland 20850
              (Address of principal executive offices and zip code)


                                  240-499-2680
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement

Cytomedix, Inc. has agreed to settle its patent infringement lawsuit against
Medtronic, Inc. which was filed on November 10, 2004, in the United States
District Court for the District of Maryland, Case No. 04-3593. In connection
with the settlement, Cytomedix entered into a license agreement with Medtronic
for all applications of Cytomedix's autologous platelet releasate therapy.

Cytomedix issued the attached press release announcing that it had agreed to
settle the patent dispute and had entered into a license agreement. The press
release is filed as Exhibit 99.1 and incorporated herein by reference.

Section 9--Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits. The following Exhibit is furnished with this Current Report on
Form 8-K:


Exhibit No.      Description
-----------      -----------

Exhibit 99.1     Press Release of Cytomedix, Inc., dated April 26, 2005.


SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                             CYTOMEDIX, INC.

                                             By: /s/ Kshitij Mohan
                                                 -------------------------------
                                                     Kshitij Mohan
                                                     Chief Executive Officer


Date:  April 27, 2005
{"company-data": {"conformed-name": "CYTOMEDIX INC", "cik": "0001091596", "assigned-sic": "8731", "irs-number": "232958959", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28443", "film-number": "05777447"}, "business-address": {"street1": "1523 BOWMAN RD SUITE A", "city": "LITTLE ROCK", "state": "AR", "zip": "72211", "phone": "5012258400"}, "mail-address": {"street1": "1523 BOWMAN RD SUITE A", "city": "LITTLE ROCK", "state": "AR", "zip": "72211"}, "former-company": {"former-conformed-name": "AUTOLOGOUS WOUND THERAPY INC", "date-changed": "20000407"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                         Date of Report: April 27, 2005

                                 CYTOMEDIX, INC.
             (Exact name of registrant as it appears in its charter)

            Delaware                     0-28443                  23-3011702
(State or other jurisdiction    (Commission File Number)         (IRS Employer
      of incorporation)                                      Identification No.)

                         416 Hungerford Drive, Suite 330
                            Rockville, Maryland 20850
              (Address of principal executive offices and zip code)

                                  240-499-2680
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement

Cytomedix, Inc. has agreed to settle its patent infringement lawsuit against
Medtronic, Inc. which was filed on November 10, 2004, in the United States
District Court for the District of Maryland, Case No. 04-3593. In connection
with the settlement, Cytomedix entered into a license agreement with Medtronic
for all applications of Cytomedix's autologous platelet releasate therapy.

Cytomedix issued the attached press release announcing that it had agreed to
settle the patent dispute and had entered into a license agreement. The press
release is filed as Exhibit 99.1 and incorporated herein by reference.

Section 9--Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits. The following Exhibit is furnished with this Current Report on
Form 8-K:

Exhibit No.      Description
-----------      -----------

Exhibit 99.1     Press Release of Cytomedix, Inc., dated April 26, 2005.

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             CYTOMEDIX, INC.

                                             By: /s/ Kshitij Mohan
                                                 -------------------------------
                                                     Kshitij Mohan
                                                     Chief Executive Officer

Date:  April 27, 2005